Aspartic acid proteases as therapeutic targets:
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Weinheim
Wiley-VCH
2010
|
| Schriftenreihe: | Methods and principles in medicinal chemistry
45 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXIII, 615 S. Ill., graph. Darst. |
| ISBN: | 9783527318117 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV025580826 | ||
| 003 | DE-604 | ||
| 005 | 20120809 | ||
| 007 | t | ||
| 008 | 100417s2010 ad|| |||| 00||| eng d | ||
| 020 | |a 9783527318117 |9 978-3-527-31811-7 | ||
| 035 | |a (OCoLC)699557048 | ||
| 035 | |a (DE-599)BVBBV025580826 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-11 |a DE-355 | ||
| 082 | 0 | |a 615.19 |2 22//ger | |
| 084 | |a VS 5350 |0 (DE-625)147687:253 |2 rvk | ||
| 084 | |a WD 5200 |0 (DE-625)148195: |2 rvk | ||
| 245 | 1 | 0 | |a Aspartic acid proteases as therapeutic targets |c ed. by Arun K. Ghosh |
| 264 | 1 | |a Weinheim |b Wiley-VCH |c 2010 | |
| 300 | |a XXIII, 615 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Methods and principles in medicinal chemistry |v 45 | |
| 650 | 0 | 7 | |a Aspartatproteasen |0 (DE-588)4290183-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Targeted drug delivery |0 (DE-588)4302415-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Aspartatproteasen |0 (DE-588)4290183-2 |D s |
| 689 | 0 | 1 | |a Targeted drug delivery |0 (DE-588)4302415-4 |D s |
| 689 | 0 | 2 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Ghosh, Arun K. |4 edt | |
| 830 | 0 | |a Methods and principles in medicinal chemistry |v 45 |w (DE-604)BV035418617 |9 45 | |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020178199&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-020178199 | ||
Datensatz im Suchindex
| _version_ | 1804142760007041024 |
|---|---|
| adam_text | CONTENTS LIST OF CONTRIBUTORS XV PREFACE XIX A PERSONAL FOREWORD XXI
PART ONE OVERVIEW OF ASPARTIC ACID PROTEASES 1 1 INTRODUCTION TO THE
ASPARTIC PROTEINASE FAMILY 3 BEN M. DUNN 1.1 INTRODUCTION 3 1.2 SEQUENCE
ALIGNMENT AND FAMILY TREE 4 1.3 THREE-DIMENSIONAL STRUCTURE 5 1.4
CONFERENCES AND PROGRESS 13 1.5 EXPLORATION OF THE ACTIVE SITES OF
ASPARTIC PROTEINASE AND RELATION TO DRUG DISCOVERY 15 REFERENCES 19 2
ASPARTIC PROTEASES: STRUCTURE, FUNCTION, AND INHIBITION 23 JORDAN TANG
2.1 INTRODUCTION 23 2.2 STRUCTURES OF ASPARTIC PROTEASES 25 2.2.1
ASPARTIC PROTEASES OF THE PEPSIN FAMILY 25 2.2.2 ASPARTIC PROTEASES
INVOLVED IN INTRAMEMBRANE PROTEOLYSIS 28 2.3 CATALYTIC MECHANISM AND
SUBSTRATE SPECIFICITY 28 2.3.1 CATALYTIC MECHANISM OF ASPARTIC PROTEASES
OF THE PEPSIN FAMILY 28 2.3.2 SPECIFICITY OF ASPARTIC PROTEASES OF THE
PEPSIN FAMILY 29 2.3.3 CATALYTIC MECHANISM OF INTRAMEMBRANE ASPARTIC
PROTEASES 30 2.4 ZYMOGEN ACTIVATION 31 BIBLIOGRAFISCHE INFORMATIONEN
HTTP://D-NB.INFO/1000249891 DIGITALISIERT DURCH VI CONTENTS 2.7
INFORMATION RESOURCE ON ASPARTIC PROTEASES 38 REFERENCES 39 3 HUMAN
ASPARTIC PROTEINASES 43 JOHN KAY AND DANIEL BUR 3.1 INTRODUCTION 43 3.2
HUMAN ASPARTIC PROTEINASES 44 3.2.1 PEPSIN(OGEN) 44 3.2.2
(PROJGASTRICSIN 48 3.2.3 (PRO)RENIN 51 3.2.4 (PRO)CATHEPSIN D 53 3.2.5
(PRO)CATHEPSIN E 54 3.3 NEW HUMAN ASPARTIC PROTEINASES 59 3.3.1
(PRO)NAPSIN A 59 3.3.2 (PRO)NAPSIN B 61 3.4 CONCLUDING REMARKS 64
REFERENCES 64 4 STRUCTURE-BASED DRUG DESIGN STRATEGIES FOR INHIBITION OF
ASPARTIC PROTEINASES 71 JON B. COOPER 4.1 INTRODUCTION 72 4.2 ASSOCIATED
DISEASE STATES 72 4.2.1 HYPERTENSION 72 4.2.2 AIDS 73 4.2.3 AMYLOID
DISEASE 74 4.2.4 CANDIDIASIS 76 4.2.5 PEPTIC ULCER DISEASE 76 CONTENTS
VII 4.6.1 THE PROBLEM OF DRUG RESISTANCE WITH HIV 95 4.7 STRUCTURE-BASED
DRUG DESIGN FOR OTHER ASPARTIC PROTEINASES 96 4.8 POSSIBLE NEW LEADS
FROM MACROMOLECULAR INHIBITOR COMPLEXES AND ZYMOGEN STRUCTURES 97 4.9
CONCLUSIONS 99 REFERENCES 99 PART TWO HIV-1 PROTEASE AS TARGET FOR THE
TREATMENT OF HIV/AIDS 107 5 HIV-1 PROTEASE: ROLE IN VIRAL REPLICATION,
PROTEIN-LIGAND X-RAY CRYSTAL STRUCTURES AND INHIBITOR DESIGN 109 IRENE
T. WEBER AND YUAN-FANG WANG 5.1 INTRODUCTION 109 5.2 HIV-1 AND THE AIDS
PANDEMIC 110 5.2.1 HIV GENOME AND LIFE CYCLE DEFINE TARGETS FOR
ANTIVIRAL THERAPY 110 5.2.2 HIV PROTEASE IS ESSENTIAL FOR VIRAL
MATURATION 112 5.2.3 SUBSTRATE SPECIFICITY OF HIV-1 PR 113 5.2.4 X-RAY
CRYSTAL STRUCTURES OF HIV-1 PR 323 5.2.5 REACTION MECHANISM OF HIV PR
115 5.3 PR INTERACTIONS WITH PEPTIDIC INHIBITORS AND DESIGN OF FIRST
ANTIVIRAL INHIBITORS 117 5.4 PR-INHIBITOR INTERACTIONS REVEALED IN
ATOMIC RESOLUTION STRUCTURES 119 5.5 THE CHALLENGE OF DRUG RESISTANCE IN
HIV 123 VIII CONTENTS 7 SECOND-GENERATION APPROVED HIV PROTEASE
INHIBITORS FOR THE TREATMENT OF H IV/AI DS 269 ARUN K. GHOSH AND BRUNO
D. CHAPSAL 7.1 INTRODUCTION 169 7.2 SECOND-GENERATION PROTEASE
INHIBITORS 171 7.2.1 LOPINAVIR 272 7.2.2 ATAZANAVIR 275 7.2.2.1 CTP-518:
A PARTIALLY DEUTERATED VERSION OF ATAZANAVIR WITH IMPROVED ADME
PROPERTIES 279 7.2.3 FOSAMPRENAVIR 280 7.2.4 TIPRANAVIR 282 7.2.5
DARUNAVIR AND SUBSEQUENT INVESTIGATIONAL BIS-THF-BASED PROTEASE
INHIBITORS 287 7.2.5.1 BRECANAVIR (BCV, GW640385) 188 7.2.5.2 NOVEL
BIS-THF-BASED GS-8374 189 7.2.5.3 SPI-256 290 7.2.6 RECENT
INVESTIGATIONAL INHIBITORS 290 7.2.6.1 PL100 290 7.3 CONCLUSION 294
REFERENCES 295 8 DARUNAVIR, A NEW PI WITH DUAL MECHANISM: FROM A NOVEL
DRUG DESIGN CONCEPT TO NEW HOPE AGAINST DRUG-RESISTANT HIV 205 ARUN K.
GHOSH, BRUNO D. CHAPSAL, AND HIROAKI MITSUYA 8.1 INTRODUCTION 205 8.2
MOLECULAR INSIGHTS FROM PROTEIN-LIGAND X-RAY CRYSTAL STRUCTURES OF EARLY
PIS AND DESIGN OF NOVEL PIS INSPIRED BY NATURE 207 8.3 DESIGN OF NOVEL
PROTEASE INHIBITORS CONTAINING CYCLIC AND POLYCYDIC ETHER TEMPLATES 209
8.3. CONTENTS IX 8.9 OPTICALLY ACTIVE SYNTHESIS OF BIS-THF LIGAND FOR
INITIAL CLINICAL STUDIES AND BEYOND 224 8.10 PHARMACOLOGICAL PROFILE OF
DARUNAVIR: ADME PROPERTIES 225 8.10.1 ABSORPTION 226 8.10.2 DISTRIBUTION
227 8.10.3 METABOLISM AND EXCRETION 227 8.11 THERAPEUTIC EVALUATION OF
DRV 228 8.11.1 CLINICAL EFFICACY 228 8.11.2 SAFETY AND TOLERABILITY 230
8.11.3 RESISTANCE PROFILE OF DARUNAVIR 232 8.11.4 DARUNAVIR AND THE
PREVIOUSLY IMPLAUSIBLE PROSPECTIVE OF HIV MONOTHERAPY 232 8.11.5
CLINICAL USE OF DARUNAVIR AND COST-EFFICACY 234 8.12 CONCLUSION 234
REFERENCES 235 9 DEVELOPMENT OF HIV-1 PROTEASE INHIBITORS,
ANTIRETROVIRAL RESISTANCE, AND CURRENT CHALLENGES OF HIV/AIDS MANAGEMENT
245 HIROAKI MITSUYA AND ARUN K. GHOSH 9.1 INTRODUCTION 245 9.2 TARGETING
THE VIRAL PROTEASE 246 9.3 THE ROLE OF PIS AND THE CHALLENGES FACED BY
HAART 247 9.4 BOOSTING : A CRITICAL MODIFICATION TO THE CLINICAL
EFFICACY OF PIS 249 9. X CONTENTS 10.3.2 BIOCHEMICAL CONSEQUENCES OF
DIFFERENT MODES OF RAAS BLOCKADE 269 10.4 HISTORY OF THE RENIN INHIBITOR
PROJECT IN CIBA-GEIGY/NOVARTIS 269 10.5 NEW CONCEPT TOWARD (P3-P1)
TOPOLOGICAL PEPTIDOMIMETIC INHIBITORS 272 10.6 EARLY PRECLINICAL LEADS
274 10.6.1 THE TETRAHYDROQUINOLINE SERIES 274 10.6.2 THE PHENOXY
SERIES: THE ROAD TO ALISKIREN 276 10.6.3 MULTIPLE CHEMOTYPE (S 3 -S!)
TOPOLOGICAL TRANSITION-STATE ANALOGUES 279 10.7 SCALABLE SYNTHESIS
DEVELOPMENT OF ALISKIREN 280 10.8 PROPERTIES OF ALISKIREN 282 10.8.1
BIOCHEMICAL AND PHARMACOLOGICAL PROPERTIES 282 10.8.2 EFFECTS OF
ALISKIREN IN ANIMAL CARDIOVASCULAR DISEASE MODELS 284 10.8.3 ABSORPTION,
DISTRIBUTION, METABOLISM, AND SAFETY PROPERTIES OF ALISKIREN IN
PRECLINICAL MODELS 285 10.8.4 CLINICAL PHARMACOKINETICS AND INTERACTIONS
WITH OTHER DRUGS 286 10.8.5 PHARMACODYNAMIC EFFECTS OF ALISKIREN ON
COMPONENTS OF THE RAAS 287 10.8.6 CLINICAL SAFETY PROFILE OF ALISKIREN
287 10. CONTENTS XI PART FOUR 7-SECRETASE AS TARGET FOR THE TREATMENT OF
ALZHEIMER S DISEASE 325 12 7-SECRETASE: AN UNUSUAL ENZYME WITH MANY
POSSIBLE DISEASE TARGETS, INCLUDING ALZHEIMER S DISEASE 327 JOHAN
LUNDKVIST AND URBAN LENDAHL 12.1 INTRODUCTION 328 12.2 PRESENILIN: FROM
A ZYMOGEN TO THE SUBUNIT OF A COMPLEX ENZYME 329 12.3 Y-SECRETASE: A
PROMISCUOUS ENZYME THAT MEDIATES REGULATED INTRAMEMBRANE PROTEOLYSIS 333
12.4 STRUCTURE OF Y-SECRETASE 335 12.5 MECHANISM OF Y-SECRETASE 336 12.6
PHARMACOLOGY OF Y-SECRETASE 337 YLJ CONCLUDING REMARKS 343 REFERENCES
343 13 7-SECRETASE INHIBITION: AN OVERVIEW OF DEVELOPMENT OF INHIBITORS
FOR THE TREATMENT OF ALZHEIMER S DISEASE 353 CHRISTOPHER L HAMBLETT,
SANJIV SHAH, RICHARD HEIDEBRECHT, JR., AND BENITO MUNOZ 13.1
INTRODUCTION 354 13.2 APP GENETICS 356 13.3 AMYLOID CASCADE HYPOTHESIS
358 13.3.1 PRESENILIN GENETICS 358 13.4 Y-SECRETASE INHIBITORS:
COMPOUNDS AND CLINICAL RESULTS 360 13.5 NOTCH-SPARING Y-SECRETASE
INHIBITORS: COMPOUNDS AN XII CONTENTS 15 THE DISCOVERY OF SS-SECRETASE
AND DEVELOPMENT TOWARD A CLINICAL INHIBITOR FOR AD: AN EXCITING ACADEMIC
COLLABORATION 423 JORDAN TANG, LIN HONG, AND ARUN K. GHOSH 15.1
INTRODUCTION 413 15.2 DISCOVERY OF MEMAPSIN 2 AND ITS IDENTIFICATION AS
SS-SECRETASE (BY JORDAN TANG) 424 15.2.1 ENZYMATIC PROPERTIES AND
INHIBITION OF MEMAPSIN 2 (BY FORDAN TANG) 426 15.3 DESIGN OF THE FIRST
SUBSTRATE-BASED INHIBITORS: A REMARKABLE SCIENTIFIC ADVENTURE BETWEEN
TWO LABORATORIES (BY JORDAN TANG AND ARUN GHOSH) 426 15.3.1 LEU-ALA
DESIGN IMPLEMENTATION AT MY LABORATORY (BY ARUN GHOSH) 428 15.3.2
EXCITING RESULTS WITH THE LEU-ALA DESIGN (BY JORDAN TANG AND ARUN GHOSH)
420 15.4 CRYSTAL STRUCTURE OF MEMAPSIN 2 AND BINDING OF INHIBITORS (BY
LIN HONG) 422 15.4.1 MEMAPSIN 2 STRUCTURE 422 15.4.2 MEMAPSIN 2
INTERACTIONS WITH INHIBITORS 423 15.5 EVOLUTION OF MEMAPSIN 2 INHIBITORS
(BY ARUN GHOSH) 424 15.5.1 EARLY STRUCTURE-ACTIVITY STUDIES 425 15.5.2
STRUCTURE-BASED DESIGN OF MACROCYCLIC INHIBITORS 428 15.5.3 DESIGN AND
DEVELOPMENT OF SELECTIVE MEMAPSIN 2 INHIBITORS 429 15.5.4
STRUCTURE-BASED DESIGN OF DIVERSE STRUCTURAL LEADS 432 15.5. CONTENTS
XIII 17.5 2-AMINOPYRIDINE AND PYRIMIDINE-BASED INHIBITORS 486 17.6
AMINOIMIDAZOPYRIMIDINE-BASED INHIBITORS 488 17.7
2-AMINOQUINAZOLINE-BASED INHIBITORS 490 17.8 PIPERIDINE AND
PIPERAZINE-BASED INHIBITORS 492 17.9 OTHER MISCELLANEOUS SCAFFOLDS 495
17.10 CONCLUSIONS 500 REFERENCES 500 PART SIX PLASMEPSINS AND OTHER
ASPARTIC PROTEASES AS DRUG TARGETS 52 2 18 THE PLASMEPSIN FAMILY AS
ANTIMALARIAL DRUG TARGETS 513 ADAMJ. RUBEN, YOSHIAKI KISO AND ERNESTO
FREIRE 18.1 INTRODUCTION 514 18.2 PLASMEPSINS IN VIVO 514 18.2.1
PLASMEPSIN FUNCTION 515 18.2.2 PLASMEPSINS AS DRUG DESIGN TARGETS 517
18.3 PLASMEPSINS IN VITRO 518 18.4 PLASMEPSIN FAMILY STRUCTURES 522
18.4.1 STRUCTURE-BASED INSIGHTS INTO PLASMEPSIN FUNCTION 523 18.4.2
ACTIVATION 523 18.4.3 QUATERNARY STRUCTURE 523 18.5 PLASMEPSIN
INHIBITORS 528 18.6 CONCLUSIONS 535 REFERENCE XIV CONTENTS 20.3
PHYLOGENY OF FUNGAL ASPARTIC PROTEASES 582 20.3.1 ASPARTIC PROTEASES IN
ASCOMYCETE YEASTS (SUBPHYLUM SACCHAROMYCOTINA) (FIGURE 20.2) 584 20.3.2
ASPARTIC PROTEASES IN FILAMENTOUS FUNGI (MUCOROUS FUNGI, BASIDIOMYCETES,
AND FILAMENTOUS ASCOMYCETES) 585 20.4 PRODUCTION OF FUNGAL ASPARTIC
PROTEASES 585 20.5 BIOLOGICAL FUNCTIONS OF ASPARTIC PROTEASES IN FUNGI
588 20.5.1 MAJOR SECRETED PROTEASES 588 20.5.2 VACUOLAR ASPARTIC
PROTEASES 588 20.5.3 BARRIERPEPSIN 589 20.5.4 YAPSINS 589 20.5.5 OTHER
ASPARTIC PROTEASE FUNCTIONS 590 20.6 SECRETED ASPARTIC PROTEASES IN
VIRULENCE OF C. ALBICANS 590 20.7 FUNCTIONS OF ASPARTIC PROTEASE IN C.
ALBICANS VIRULENCE PROCESSES 592 20.8 SECRETED ASPARTIC PROTEASES IN THE
VIRULENCE OF CANDIDA SPECIES OTHER THAN C. ALBICANS 593 20.9 SECRETED
ASPARTIC PROTEASES DURING INFECTION BY OPPORTUNISTIC FILAMENTOUS FUNGI
594 20.10 FUNGAL ASPARTIC PROTEASES AS POSSIBLE DRUG TARGETS 594 20.1
|
| any_adam_object | 1 |
| author2 | Ghosh, Arun K. |
| author2_role | edt |
| author2_variant | a k g ak akg |
| author_facet | Ghosh, Arun K. |
| building | Verbundindex |
| bvnumber | BV025580826 |
| classification_rvk | VS 5350 WD 5200 |
| ctrlnum | (OCoLC)699557048 (DE-599)BVBBV025580826 |
| dewey-full | 615.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.19 |
| dewey-search | 615.19 |
| dewey-sort | 3615.19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Biologie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01739nam a2200421 cb4500</leader><controlfield tag="001">BV025580826</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20120809 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">100417s2010 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527318117</subfield><subfield code="9">978-3-527-31811-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)699557048</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV025580826</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-11</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.19</subfield><subfield code="2">22//ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 5350</subfield><subfield code="0">(DE-625)147687:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WD 5200</subfield><subfield code="0">(DE-625)148195:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Aspartic acid proteases as therapeutic targets</subfield><subfield code="c">ed. by Arun K. Ghosh</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim</subfield><subfield code="b">Wiley-VCH</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXIII, 615 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Methods and principles in medicinal chemistry</subfield><subfield code="v">45</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Aspartatproteasen</subfield><subfield code="0">(DE-588)4290183-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Targeted drug delivery</subfield><subfield code="0">(DE-588)4302415-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Aspartatproteasen</subfield><subfield code="0">(DE-588)4290183-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Targeted drug delivery</subfield><subfield code="0">(DE-588)4302415-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghosh, Arun K.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Methods and principles in medicinal chemistry</subfield><subfield code="v">45</subfield><subfield code="w">(DE-604)BV035418617</subfield><subfield code="9">45</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020178199&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-020178199</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV025580826 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T22:36:53Z |
| institution | BVB |
| isbn | 9783527318117 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-020178199 |
| oclc_num | 699557048 |
| open_access_boolean | |
| owner | DE-11 DE-355 DE-BY-UBR |
| owner_facet | DE-11 DE-355 DE-BY-UBR |
| physical | XXIII, 615 S. Ill., graph. Darst. |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Wiley-VCH |
| record_format | marc |
| series | Methods and principles in medicinal chemistry |
| series2 | Methods and principles in medicinal chemistry |
| spelling | Aspartic acid proteases as therapeutic targets ed. by Arun K. Ghosh Weinheim Wiley-VCH 2010 XXIII, 615 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Methods and principles in medicinal chemistry 45 Aspartatproteasen (DE-588)4290183-2 gnd rswk-swf Targeted drug delivery (DE-588)4302415-4 gnd rswk-swf Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Aspartatproteasen (DE-588)4290183-2 s Targeted drug delivery (DE-588)4302415-4 s Arzneimittelentwicklung (DE-588)4143176-5 s DE-604 Ghosh, Arun K. edt Methods and principles in medicinal chemistry 45 (DE-604)BV035418617 45 DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020178199&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Aspartic acid proteases as therapeutic targets Methods and principles in medicinal chemistry Aspartatproteasen (DE-588)4290183-2 gnd Targeted drug delivery (DE-588)4302415-4 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd |
| subject_GND | (DE-588)4290183-2 (DE-588)4302415-4 (DE-588)4143176-5 (DE-588)4143413-4 |
| title | Aspartic acid proteases as therapeutic targets |
| title_auth | Aspartic acid proteases as therapeutic targets |
| title_exact_search | Aspartic acid proteases as therapeutic targets |
| title_full | Aspartic acid proteases as therapeutic targets ed. by Arun K. Ghosh |
| title_fullStr | Aspartic acid proteases as therapeutic targets ed. by Arun K. Ghosh |
| title_full_unstemmed | Aspartic acid proteases as therapeutic targets ed. by Arun K. Ghosh |
| title_short | Aspartic acid proteases as therapeutic targets |
| title_sort | aspartic acid proteases as therapeutic targets |
| topic | Aspartatproteasen (DE-588)4290183-2 gnd Targeted drug delivery (DE-588)4302415-4 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd |
| topic_facet | Aspartatproteasen Targeted drug delivery Arzneimittelentwicklung Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020178199&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV035418617 |
| work_keys_str_mv | AT ghosharunk asparticacidproteasesastherapeutictargets |